Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective-Reference-Cited by-同舟云学术

Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective

Published:2022-01 Issue: Volume:169 Page:103569
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Cabezas-Camarero Santiago^ORCID,Pérez-Segura Pedro^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference51 articles.

1. Signatures of mutational processes in human cancer;Alexandrov;Nature,2014

2. Anti-tumor immunity in head and neck cancer: Understanding the evidence, how tumors escape and immunotherapeutic approaches;Allen;Cancers (Basel),2015

4. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: a review of the literature;Bossi;Crit. Rev. Oncol. Hematol. [Internet],2019

5. Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial;Bourhis;Ann. Oncol.,2021

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

2. Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial;Journal of the Endocrine Society;2024-07-12

3. Surgical margins in head and neck squamous cell carcinoma: a narrative review;International Journal of Surgery;2024-03-11

4. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma;Clinical Cancer Research;2024-03-08

5. Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer;Current Opinion in Oncology;2024-02-07